34844-79-6

Basic information

• Product Name: methyl (2-cyanophenoxy)acetate
• Synonyms: methyl (2-cyanophenoxy)acetate
• CAS NO: 34844-79-6
• Molecular Formula: C₁₀H₉NO₃
• Molecular Weight: 191.19
• Mol File: 34844-79-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: methyl (2-cyanophenoxy)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (2-cyanophenoxy)acetate(34844-79-6)
• EPA Substance Registry System: methyl (2-cyanophenoxy)acetate(34844-79-6)

Safety Data

• Hazardous Substances Data: 34844-79-6(Hazardous Substances Data)

Upstream product

• 611-20-1 salicylonitrile 
• 584-08-7 potassium carbonate 
• 96-32-2 bromoacetic acid methyl ester 

Downstream Products

• 17775-01-8 2.3.4.5-Tetrahydro-benzo[f][1,4]oxazepine 
• 39786-36-2 4-oxo-3,4-dihydrobenzofuro<3,2-d>pyrimidine 
• 39876-88-5 4-Chlorobenzofuro<3,2-d>pyrimidine 
• 57805-85-3 methyl 3-amino-2-benzofurancarboxylate 
• 34844-80-9 4,5-dihydro-1,4-benzoxazepin-3(2H)-one 

Relevant articles and documents

1,3-dipolar cycloaddition in the preparation of new fused heterocyclic compounds via thermal initiation

This paper describes the synthesis of precursors with a benzo[b]furan skeleton for the intramolecular 1,3-dipolar cycloaddition of azomethine ylides prepared from N-substituted 3-allyl-aminobenzo[b]furan-2-aldehydes and secondary amines derived from α-amino acid esters. Reactions were initiated by heating. The products consisted of four fused rings with three stereogenic centers. Their structure and stereochemistry were determined by NMR spectra and X-ray measurements.

Discovery of Benzoazepinequinoline (BAQ) Derivatives as Novel, Potent, Orally Bioavailable Respiratory Syncytial Virus Fusion Inhibitors

A novel benzoazepinequnoline (BAQ) series was discovered as RSV fusion inhibitors. BAQ series originated from compound 2, a hit from similarity-based virtual screening. In SAR exploration, benzoazepine allowed modifications in the head moiety. Benzylic sulfonyl on benzoazepine and 6-Me on quinoline were crucial for good anti-RSV activity. Although the basic amine in the head portion was crucial for anti-RSV activity, the attenuated basicity was required to reduce Vss. Introducing oxetane to the head portion led to discovery of compound 1, which demonstrated single-digit nM anti-RSV activity against different RSV strains, reasonable oral exposure in plasma, and 78-fold higher exposure in lung. Compound 1 also displayed 1 log viral reduction in a female BALB/c mice RSV model by b.i.d. oral dosing at 12.5 mg/kg. A single resistant mutant at L138F in fusion protein proved compound 1 to be a RSV fusion inhibitor.

Tyrosine kinase inhibitors. 16. 6,5,6-Tricyclic benzothieno[3,2-d]pyrimidines and pyrimido[5,4-b]- and -[4,5- b]indoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase

Several elaborations of the fundamental anilinopyrimidine pharmacophore have been reported as potent and selective inhibitors of the epidermal growth factor receptor (EGFr) tyrosine kinase. This paper reports on a series of inhibitors whereby some 6,5-bicyclic heteroaromatic systems were fused through their C-2 and C-3 positions to this anilinopyrimidine pharmacophore. Although the resulting tricycles did not produce the enormous potency of some of the (5/6),6,6-bicyclic systems, the best of them had IC50s for the EGFr TK around 1 nM. Investigation of 4-position side chains in the indolopyrimidines confirmed that m-bromoaniline was an optimal substituent for potency. Investigation of substitution within the C-(benzo)ring of benzothienopyrimidines confirmed that introduction of an extra ring can change sharply the effects of substituents when compared to similar bicyclic nuclei, and only two substituents were found which even moderately enhanced inhibitory activity over the parent compound for this series.